What Are Antiarrhythmic Drugs? Types and Side Effects

Antiarrhythmic drugs are medications designed to correct abnormal heart rhythms by altering the electrical activity of cardiac cells. They work by targeting ion channels and receptors that control how electrical signals travel through the heart, slowing conduction, extending recovery periods between beats, or dampening overactive nerve signals. Despite their name, these drugs carry a well-known paradox: they can sometimes provoke the very arrhythmias they are meant to treat, a problem that has shaped how cardiologists prescribe them for decades.

How They Are Classified

The most widely used system for organizing antiarrhythmic drugs was introduced by the British pharmacologist Edward Miles Vaughan Williams. His original framework defined three classes of drug action based on their primary electrical effect on heart cells: sodium channel blockade (Class I), suppression of sympathetic nervous system activity (Class II), and prolongation of the action potential duration (Class III). A fourth class, calcium channel antagonism, was added later as drugs like verapamil entered clinical use.¹

This four-class scheme has been the go-to reference for students and clinicians for over half a century, largely because it is simple and easy to remember. It has also been criticized, though. Many antiarrhythmic drugs act on more than one type of ion channel, so they do not fit neatly into a single class. More seriously, the classification did not predict that some Class I drugs would increase mortality in heart attack survivors, a finding that shook the field in the early 1990s. An attempt to replace the system with a more comprehensive framework called the Sicilian Gambit never caught on because it was too complex for everyday clinical use.

A modernized version of the Vaughan Williams system, published in 2018, keeps the four original classes but adds subcategories to reflect what scientists now know about different sodium current components, potassium channel subtypes, and calcium-handling molecules. It also introduces new classes for targets like the ion channels involved in the heart’s natural pacemaker activity, gap junctions that allow electrical signals to pass between cells, and signaling pathways that drive long-term structural remodeling of heart tissue.²

Class I: Sodium Channel Blockers

Class I drugs work by blocking the fast sodium channels that are responsible for the initial rapid electrical impulse in heart muscle cells. By slowing or reducing that impulse, they can interrupt abnormal circuits that sustain arrhythmias. The class is split into three subgroups based on how strongly and how quickly they bind to sodium channels, and how they affect other electrical properties of the heart.

Class Ia drugs, including quinidine, procainamide, and disopyramide, slow the initial electrical impulse and also prolong the time the heart cell needs to recover before it can fire again. At normal doses, quinidine can lengthen the QT interval on an electrocardiogram, and with increasing blood levels it progressively depresses the heart’s ability to conduct signals. Quinidine is also notorious for causing “quinidine syncope,” a fainting episode caused by a dangerous rhythm called torsades de pointes, which can happen even at standard doses and often within the first few days of treatment. Beyond the heart, quinidine frequently causes gastrointestinal symptoms and allergic-type reactions like fever, rash, and liver inflammation. Procainamide shares many of quinidine’s electrical effects but is particularly associated with a drug-induced form of lupus, an autoimmune condition that can require stopping the medication.³

Class Ib drugs, such as lidocaine and mexiletine, work differently. They have a weaker, faster-on-and-off interaction with sodium channels and have minimal effect on the recovery period. Mexiletine blocks both the fast and late sodium currents in heart tissue.⁴ These drugs are most useful for arrhythmias linked to damaged or oxygen-starved heart tissue, because their electrical effects are more pronounced in partially injured cells than in healthy ones. Their action is also “use-dependent,” meaning they block channels more aggressively in cells that are firing rapidly, which is exactly the behavior you want to suppress during a fast arrhythmia.⁵

Class Ic drugs, including flecainide and propafenone, are the most potent sodium channel blockers of the three subgroups. They slow conduction substantially but have little effect on recovery time. They are effective against certain supraventricular arrhythmias, but their use in patients with structural heart disease is severely restricted because of the Cardiac Arrhythmia Suppression Trial (CAST), one of the most important safety studies in cardiology history.

The Trial That Changed Everything

In the late 1980s, it seemed logical that suppressing extra heartbeats in patients who had survived a heart attack would prevent sudden cardiac death. The CAST study tested this idea with two Class Ic drugs, encainide and flecainide. The results were the opposite of what everyone expected. After an average follow-up of ten months, patients taking the drugs died of arrhythmia at roughly three times the rate of those on placebo: 43 arrhythmic deaths in the drug group versus 16 on placebo. Deaths from other cardiac causes were also higher in the drug group.⁶

CAST transformed how physicians think about antiarrhythmic drugs. The lesson was that suppressing an arrhythmia on a monitor does not necessarily mean the patient is safer. The drugs were creating new, lethal rhythm disturbances in scarred heart tissue. This finding is the reason cardiologists today are cautious about using Class Ic agents in anyone with a prior heart attack or significant structural heart disease, and it is a large part of why the entire field moved toward more selective, carefully monitored use of these medications.⁷

Class II: Beta-Blockers

Beta-blockers such as metoprolol, atenolol, and propranolol are among the most commonly prescribed heart medications in the world, and their antiarrhythmic properties are a major reason why. They work by blocking the effects of adrenaline and related stress hormones on the heart. Overactive sympathetic nerve signaling has been directly linked to dangerous ventricular arrhythmias and sudden death, and beta-blockers counteract this through several mechanisms: they slow the heart rate, reduce the tendency of heart cells to fire spontaneously, and lengthen the recovery period between beats. Blocking adrenergic stimulation is considered the best-established drug strategy for preventing ventricular arrhythmias.⁸

Side effects of beta-blockers are generally more predictable and manageable than those of many other antiarrhythmic drugs. Fatigue, cold hands and feet, slow heart rate, and low blood pressure are common. In people with asthma or severe lung disease, non-selective beta-blockers can tighten the airways. Depression, sleep disturbance, and sexual dysfunction are reported by some patients. Compared to Class I and Class III drugs, though, beta-blockers rarely provoke new arrhythmias, which is one reason they remain a first-line therapy in many clinical situations.

Class III: Potassium Channel Blockers

Class III drugs, including amiodarone, sotalol, dofetilide, and ibutilide, work primarily by blocking potassium channels that are responsible for returning the heart cell to its resting state after firing. This extends the action potential duration and the refractory period, making it harder for abnormal electrical circuits to sustain themselves.

The QT-prolonging effect of these drugs comes from blocking a specific potassium current called the rapid component of the delayed rectifier current. Prolonging this phase of the heartbeat increases the risk of afterdepolarizations, which are abnormal electrical impulses that can trigger torsades de pointes, a potentially fatal arrhythmia.⁹ For this reason, drugs like dofetilide and sotalol require in-hospital initiation with continuous heart monitoring, and regular electrocardiograms to track QT interval changes.

Amiodarone deserves special mention because it is arguably the most effective antiarrhythmic drug available, yet also one of the most toxic. Unlike other Class III agents, amiodarone acts on sodium, potassium, and calcium channels simultaneously and also has beta-blocking properties, which makes it unusually versatile. But it accumulates in tissues throughout the body, and long-term use can damage the lungs, liver, thyroid, skin, and eyes. Cases of simultaneous toxicity in multiple organ systems have been documented.¹⁰ Patients on amiodarone need regular blood tests for thyroid and liver function, periodic chest imaging to check for lung damage, and eye exams. Its extraordinarily long half-life, sometimes measured in months, means that side effects can persist long after the drug is stopped.

Class IV: Calcium Channel Blockers

Only certain calcium channel blockers have meaningful antiarrhythmic effects: verapamil and diltiazem. A third calcium channel blocker, nifedipine, actually speeds up conduction through the AV node rather than slowing it, so it is not useful for arrhythmia control and can even worsen some rhythm disturbances.¹¹ This distinction matters because patients sometimes assume all calcium channel blockers are interchangeable.

Verapamil and diltiazem slow conduction through the AV node, making them effective for controlling the heart rate in atrial fibrillation and for terminating certain supraventricular tachycardias that use the AV node as part of their circuit. The two drugs produce a similar degree of AV nodal slowing, though verapamil extends the AV node’s recovery period more than diltiazem does.¹² Verapamil is also the more potent suppressor of the heart’s pumping strength, which is why it must be used cautiously in patients with heart failure. Both drugs can cause low blood pressure, constipation (especially verapamil), and excessive slowing of the heart rate.¹³

Agents That Do Not Fit the Four Classes

Several important antiarrhythmic agents fall outside the traditional classification. Adenosine is given as a rapid intravenous push to terminate supraventricular tachycardias. It produces a brief, complete block of conduction through the AV node, which interrupts the re-entrant circuit responsible for the arrhythmia. The effect lasts only seconds, and the drug is cleared from the bloodstream almost immediately. Side effects are intense but fleeting: patients often feel chest tightness, flushing, and a momentary sense of dread as the heart pauses before resuming its normal rhythm.¹⁴

Magnesium sulfate, given intravenously, serves two specific roles. It is considered first-line treatment for torsades de pointes, regardless of what caused the arrhythmia, because it suppresses the abnormal afterdepolarizations that drive it. It is also effective against arrhythmias caused by digoxin toxicity, where it works by reactivating an enzyme that digoxin inhibits.¹⁵ Magnesium can also help control fast heart rates in atrial fibrillation, with one study showing it lowered ventricular rates by about 16% within five minutes of infusion.¹⁶

Proarrhythmia: When the Treatment Is the Problem

The ability of antiarrhythmic drugs to provoke new or worse arrhythmias, called proarrhythmia, is their most dangerous shared limitation. The specific type of proarrhythmia depends on the drug class. Class Ia drugs most commonly trigger torsades de pointes, a twisting, polymorphic ventricular tachycardia linked to excessive QT prolongation. Class Ic drugs, by contrast, tend to cause a sustained, monomorphic ventricular tachycardia driven by a different electrical mechanism: slowed conduction creating a continuous re-entrant loop.¹⁷ Class III drugs share the torsades de pointes risk with Class Ia agents, since both prolong repolarization and increase susceptibility to afterdepolarizations.¹⁸

Proarrhythmia risk is not evenly distributed. It is higher in patients with underlying structural heart disease, those with electrolyte imbalances (especially low potassium or magnesium), women (who tend to have longer baseline QT intervals), and patients taking other medications that affect the same electrical pathways. This is why many antiarrhythmic drugs are initiated in the hospital under continuous monitoring, and why routine electrocardiograms and blood work are part of ongoing therapy.

Drug Interactions

Antiarrhythmic drugs have a narrow therapeutic window, meaning the difference between an effective dose and a dangerous one is small. This makes drug interactions a serious practical concern. Interactions can be pharmacokinetic, where another drug interferes with how the antiarrhythmic is broken down or transported in the body, causing it to accumulate to toxic levels. They can also be pharmacodynamic, where two drugs produce additive effects on the same electrical property, most commonly QT prolongation. Amiodarone, quinidine, and dofetilide are the antiarrhythmics with the most numerous and clinically significant interactions.¹⁹

For patients, the practical takeaway is that any new medication, including over-the-counter drugs and supplements, should be checked for interactions before starting. Even something as common as a macrolide antibiotic or a grapefruit-containing product can shift blood levels of certain antiarrhythmics into a dangerous range.

Rate Control Versus Rhythm Control in Atrial Fibrillation

For atrial fibrillation, the most common sustained arrhythmia, physicians face a strategic decision: try to restore and maintain a normal rhythm using antiarrhythmic drugs or ablation (rhythm control), or accept that the heart will stay in fibrillation and simply keep the heart rate from going too fast using beta-blockers, calcium channel blockers, or digoxin (rate control). For years, large trials suggested neither approach was clearly superior for survival. A more recent meta-analysis of randomized trials found that rhythm control reduced cardiovascular death by about 22%, stroke by about 20%, and heart failure hospitalizations by about 20%, though it did not reach a statistically clear reduction in death from all causes.²⁰ This benefit was driven largely by more contemporary studies, suggesting that improvements in both drug therapy and ablation techniques over time have tipped the scale.

The picture is different for atrial fibrillation that develops after heart surgery, which is common. In that specific scenario, a randomized trial found no significant differences in hospital stay, death rates, or serious adverse events between rate control and rhythm control strategies.²¹ Post-surgical atrial fibrillation often resolves on its own as the body recovers, so aggressive rhythm control may offer little advantage in that setting.

Catheter Ablation as an Alternative

Catheter ablation, a procedure that uses heat or cold energy to destroy small areas of heart tissue responsible for triggering or sustaining arrhythmias, has become an increasingly important alternative to long-term drug therapy. A meta-analysis comparing ablation to antiarrhythmic drugs as the first treatment for symptomatic paroxysmal atrial fibrillation found that patients who underwent ablation were about 37% less likely to have any recurrence of atrial tachyarrhythmia and about 47% less likely to have symptomatic recurrence. The rates of adverse events were similar between the two groups.²²

Ablation does not work equally well for everyone, though. A secondary analysis of the CABANA trial found that ablation significantly reduced a composite of major outcomes in patients with fewer than three non-modifiable recurrence risk factors, but this benefit disappeared in patients with three or more such factors. Both groups had fewer atrial fibrillation recurrences after ablation compared to drug therapy, but the hard clinical outcomes like death and stroke only improved in the lower-risk subgroup.²³ Factors like advanced age and long-standing persistent fibrillation make it harder for ablation to deliver its full benefit.

Pregnancy and Antiarrhythmic Drugs

Arrhythmias can occur during pregnancy, sometimes for the first time, due to the cardiovascular changes that come with carrying a child: increased blood volume, faster heart rate, and hormonal shifts that affect the heart’s electrical properties. Treatment decisions during pregnancy are complicated because antiarrhythmic drugs can cross the placenta and appear in breast milk. Potential risks to the fetus include birth defects, growth restriction, and premature birth. Any antiarrhythmic prescribed during pregnancy requires an individualized approach that weighs the severity of the arrhythmia against the drug’s safety profile, with close monitoring of both the mother and fetus throughout.²⁴ Beta-blockers (particularly metoprolol and propranolol) and certain Class Ic drugs like flecainide are among those more commonly used in pregnancy when drug treatment is necessary, but none are entirely free of concern.

Genetics and Variable Drug Responses

Why one patient tolerates an antiarrhythmic drug well while another develops dangerous side effects at the same dose often has a genetic component. Variations in the genes encoding drug-metabolizing enzymes can cause some people to break down a drug slowly, leading to accumulation and toxicity, while others clear it so quickly that they never reach a therapeutic level. Genetic differences in the ion channels themselves can also matter: a patient with a subtle, clinically silent variant in a potassium channel gene may have a slightly longer QT interval at baseline, and adding a QT-prolonging drug tips them into dangerous territory.²⁵

The field of pharmacogenomics is working to incorporate this kind of genetic testing into routine prescribing decisions for cardiovascular drugs, including antiarrhythmics, anticoagulants, and statins. A patient’s genetic profile can in principle predict both how well a drug will work and how likely it is to cause harm.²⁶ In practice, genetic testing before prescribing antiarrhythmics is not yet standard outside of specialized centers, but the evidence base is growing and it is increasingly possible that a patient starting a high-risk drug like dofetilide or quinidine will eventually receive a pharmacogenetic screen as part of the workup.

What Is in the Development Pipeline

Despite the clear need for safer and more effective options, the pipeline of genuinely novel antiarrhythmic drugs has shrunk over the past few decades. The financial, regulatory, and conceptual barriers are steep: developing a cardiac drug is expensive, proving it does not cause proarrhythmia requires large, long trials, and the CAST legacy makes both regulators and companies cautious. Some of the more promising current activity involves repurposing or reformulating existing drugs for new arrhythmia-related indications rather than building entirely new molecules from scratch.²⁷ The modernized classification system’s new categories, including targets related to gap junctions, stretch-sensitive channels, and structural remodeling pathways, point to where future drug development could go, but translating those targets into approved treatments remains a slow process.